IS5420A - Heteródíazasýklóalkanar sem kólvirkir bindlar fyrir nikótínasetýlkólínviðtaka - Google Patents

Heteródíazasýklóalkanar sem kólvirkir bindlar fyrir nikótínasetýlkólínviðtaka

Info

Publication number: IS5420A
Authority: IS; Iceland
Prior art keywords: alkyl; alkoxy; cycloalkylalkyl; cycloalkyl; alkynoxy
Prior art date: 1997-10-27

Application number

IS5420A

Other languages

English (en)

Inventor

Peters Dan

M. Olsen Gunnar

Feldbæk Nielsen Simon

Original Assignee

Neurosearch A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-27

Filing date

2000-03-28

Publication date

2000-03-28

2000-03-28 Application filed by Neurosearch A/S filed Critical Neurosearch A/S

2000-03-28 Publication of IS5420A publication Critical patent/IS5420A/is

Links

239000011230 binding agent Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 10
125000003545 alkoxy group Chemical group 0.000 abstract 9
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 9
125000000753 cycloalkyl group Chemical group 0.000 abstract 9
125000003342 alkenyl group Chemical group 0.000 abstract 8
125000000304 alkynyl group Chemical group 0.000 abstract 8
125000000000 cycloalkoxy group Chemical group 0.000 abstract 8
125000001475 halogen functional group Chemical group 0.000 abstract 8
-1 methylenedioxy Chemical group 0.000 abstract 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 7
125000000623 heterocyclic group Chemical group 0.000 abstract 3
125000002950 monocyclic group Chemical group 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
108010009685 Cholinergic Receptors Proteins 0.000 abstract 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
CPQPJKVLRWQDJS-WLHGVMLRSA-N OC(=O)\C=C\C(O)=O.N1=C(Cl)C(OC)=CC(N2CCNCCC2)=C1 Chemical compound OC(=O)\C=C\C(O)=O.N1=C(Cl)C(OC)=CC(N2CCNCCC2)=C1 CPQPJKVLRWQDJS-WLHGVMLRSA-N 0.000 abstract 1
102000034337 acetylcholine receptors Human genes 0.000 abstract 1
125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
125000005036 alkoxyphenyl group Chemical group 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000003257 anti-anginal effect Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000001773 anti-convulsant effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002460 anti-migrenic effect Effects 0.000 abstract 1
230000002738 anti-smoking effect Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229940027564 cytisine Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
125000004464 hydroxyphenyl group Chemical group 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000003176 neuroleptic agent Substances 0.000 abstract 1
230000000701 neuroleptic effect Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
125000006501 nitrophenyl group Chemical group 0.000 abstract 1
230000001777 nootropic effect Effects 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000005309 thioalkoxy group Chemical group 0.000 abstract 1
229940125725 tranquilizer Drugs 0.000 abstract 1
239000003204 tranquilizing agent Substances 0.000 abstract 1
230000002936 tranquilizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/22—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing two or more pyridine rings directly linked together, e.g. bipyridyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Addiction (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IS5420A 1997-10-27 2000-03-28 Heteródíazasýklóalkanar sem kólvirkir bindlar fyrir nikótínasetýlkólínviðtaka IS5420A (is)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DK122597		1997-10-27
DK40998		1998-03-24
DK79698		1998-06-19
PCT/DK1998/000465 WO1999021834A1 (en)	1997-10-27	1998-10-27	Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors

Publications (1)

Publication Number	Publication Date
IS5420A true IS5420A (is)	2000-03-28

Family

ID=27220661

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS5420A IS5420A (is)	1997-10-27	2000-03-28	Heteródíazasýklóalkanar sem kólvirkir bindlar fyrir nikótínasetýlkólínviðtaka

Country Status (25)

Country	Link
US (2)	US6825189B1 (is)
EP (2)	EP1491532B1 (is)
JP (1)	JP4570773B2 (is)
KR (1)	KR100607838B1 (is)
CN (1)	CN1131211C (is)
AT (2)	ATE278670T1 (is)
AU (1)	AU744539B2 (is)
BR (1)	BR9813279B1 (is)
CA (1)	CA2306093C (is)
CZ (1)	CZ299499B6 (is)
DE (2)	DE69842058D1 (is)
DK (1)	DK1027336T3 (is)
EE (1)	EE04588B1 (is)
ES (1)	ES2230723T3 (is)
HU (1)	HU226859B1 (is)
IL (2)	IL135108A0 (is)
IS (1)	IS5420A (is)
NO (1)	NO317094B1 (is)
NZ (1)	NZ503520A (is)
PL (1)	PL203140B1 (is)
PT (1)	PT1027336E (is)
RU (1)	RU2205179C2 (is)
SK (1)	SK285198B6 (is)
TR (1)	TR200001171T2 (is)
WO (1)	WO1999021834A1 (is)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7214686B2 (en)	1997-06-30	2007-05-08	Targacept, Inc.	Pharmaceutical compositions and methods for effecting dopamine release
AU744539B2 (en) *	1997-10-27	2002-02-28	Neurosearch A/S	Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
WO2000064885A1 (en) *	1999-04-26	2000-11-02	Neurosearch A/S	Heteroaryl diazacycloalkanes, their preparation and use
NZ513575A (en) *	1999-05-04	2003-07-25	Neurosearch As	Heteroaryl diazabicycloalkanes useful for treating or preventing a disease or a disorder responsive to the activity of nAChR modulators
GB9914026D0 (en) *	1999-06-17	1999-08-18	Zeneca Ltd	Chemical compounds
WO2001044243A2 (en) *	1999-12-14	2001-06-21	Neurosearch A/S	Novel heteroaryl-diazabicycloalkanes
MY137020A (en) *	2000-04-27	2008-12-31	Abbott Lab	Diazabicyclic central nervous system active agents
US6809105B2 (en)	2000-04-27	2004-10-26	Abbott Laboratories	Diazabicyclic central nervous system active agents
DE60122015T2 (de)	2000-10-13	2006-11-23	Neurosearch A/S	Behandlung affektiver störungen durch kombinierte wirkung eines nikotinischen rezeptoragonisten und einer monoaminergischen substanz
CA2341952A1 (en)	2001-03-23	2002-09-23	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US8039459B2 (en)	2004-07-15	2011-10-18	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en)	2002-03-25	2013-10-15	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory diseases
EA009789B1 (ru)	2002-07-05	2008-04-28	Таргасепт, Инк.	N-арилдиазаспирациклические соединения и способы их получения и применения
AU2003254016A1 (en)	2002-07-19	2004-02-09	Catholic Healthcare West	Methods and compositions relating to chimeric nicotinic receptor subunits
US7098331B2 (en)	2003-03-05	2006-08-29	Targacept, Inc.	Arylvinylazacycloalkane compounds and methods of preparation and use thereof
GB0316915D0 (en)	2003-07-18	2003-08-20	Glaxo Group Ltd	Compounds
EP1678172B1 (en)	2003-10-15	2009-12-09	Targacept, Inc.	Azabicyclic compounds for relieving pain and treating central nervous system disorders
US20070191815A1 (en)	2004-09-13	2007-08-16	Chrono Therapeutics, Inc.	Biosynchronous transdermal drug delivery
CN101044134A (zh)	2004-09-20	2007-09-26	塔加西普特公司	具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物
EP2289510A1 (en)	2004-09-20	2011-03-02	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
MX2007003332A (es)	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
US20080167321A1 (en) *	2004-09-20	2008-07-10	Xenon Pharmaceuticals Inc.	Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
EP2269610A3 (en)	2004-09-20	2011-03-09	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP4958786B2 (ja)	2004-09-20	2012-06-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	複素環誘導体および治療薬としてのそれらの使用
MX2007003327A (es)	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
EP1799667B1 (en)	2004-09-20	2013-03-20	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as therapeutic agents
MX2007003319A (es)	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como agentes terapeuticos.
US7459469B2 (en)	2004-11-10	2008-12-02	Targacept, Inc.	Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru)	2004-11-10	2009-11-25	Таргасепт, Інк.	Гидроксибензоатные соли метаникотиновых соединений
AU2006209216A1 (en) *	2005-01-25	2006-08-03	Galenea Corp	Substituted arylamine compounds and their use as 5-HT6 modulators
FR2885615B1 (fr) *	2005-05-12	2007-06-22	Servier Lab	Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2885616B1 (fr) *	2005-05-12	2007-06-22	Servier Lab	Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BRPI0611187A2 (pt)	2005-06-03	2010-08-24	Xenon Pharmaceuticals Inc	derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
FR2889188B1 (fr) *	2005-07-28	2007-09-07	Servier Lab	Nouveaux composes 1,1-pyridinylaminocyclopropanamines polysubstitues, leur procede de preparation et les compositions phamaceutiques qui les contiennent
CA2618700A1 (en)	2005-08-22	2007-03-01	Targacept, Inc.	Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof
US20070134169A1 (en) *	2005-12-11	2007-06-14	Rabinoff Michael D	Methods for smoking cessation or alcohol cessation or other addiction cessation
TWI389889B (zh)	2006-05-09	2013-03-21	Targacept Inc	（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2021325A2 (en)	2006-05-09	2009-02-11	AstraZeneca AB	Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
US7902184B2 (en)	2006-05-30	2011-03-08	Hoffmann-La Roche Inc.	Piperazinyl pyrimidine derivatives
US20100234349A1 (en)	2006-09-04	2010-09-16	Olsen Gunnar M	Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
ES2521494T3 (es)	2007-04-02	2014-11-12	Parkinson's Institute	Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
WO2008145681A2 (en) *	2007-05-31	2008-12-04	Boehringer Ingelheim International Gmbh	Ccr2 receptor antagonists and uses thereof
KR101565469B1 (ko)	2007-10-01	2015-11-03	코멘티스, 인코포레이티드	알츠하이머병의 치료를 위한 알파 7 니코틴 아세틸콜린 수용체 리간드로서 퀴누클리딘-4-일메틸 1ｈ-인돌-3-카르복실레이트 유도체
US8697722B2 (en) *	2007-11-02	2014-04-15	Sri International	Nicotinic acetylcholine receptor modulators
DK2379525T3 (en)	2008-12-19	2015-10-19	Boehringer Ingelheim Int	Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
EP2509982A1 (en)	2009-12-07	2012-10-17	Targacept, Inc.	3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
WO2011073154A1 (en)	2009-12-17	2011-06-23	Boehringer Ingelheim International Gmbh	New ccr2 receptor antagonists and uses thereof
RU2560729C2 (ru) *	2010-01-11	2015-08-20	АСТРАЕА ТЕРАПЕУТИКС, ЭлЭлСи	Модуляторы никотиновых ацетилхолиновых рецепторов
ES2667049T3 (es)	2010-02-05	2018-05-09	Merck Patent Gmbh	Derivados de heteroaril-[1,8]naftiridina
US20110256064A1 (en) *	2010-04-16	2011-10-20	Ac Immune, S.A.	Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
US8877745B2 (en)	2010-05-12	2014-11-04	Boehringer Ingelheim International Gmbh	CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569295B1 (en)	2010-05-12	2014-11-19	Boehringer Ingelheim International GmbH	New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en)	2010-05-17	2014-09-23	Boehringer Ingelheim International Gmbh	CCR2 antagonists and uses thereof
CN103180277A (zh)	2010-05-20	2013-06-26	塔格塞普特股份有限公司	制备芳基取代的烯属胺的新方法
US9018212B2 (en)	2010-05-25	2015-04-28	Boehringer Ingelheim International Gmbh	Pyridazine carboxamides as CCR2 receptor antagonists
EP2576538B1 (en)	2010-06-01	2015-10-28	Boehringer Ingelheim International GmbH	New CCR2 antagonists
WO2012105815A2 (ko) *	2011-02-01	2012-08-09	전북대학교산학협력단	양이온성을 지닌 생분해성 ｐａｏｘ 고분자 미립구
JP5786258B2 (ja)	2011-07-15	2015-09-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規かつ選択的なｃｃｒ２拮抗薬
CN102924390B (zh) *	2012-09-07	2014-12-31	苏州康润医药有限公司	1,5-二氮杂环辛烷-1-甲酸叔丁酯的合成方法
US20170166561A1 (en)	2014-07-11	2017-06-15	Alpharmagen, Llc	Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity
WO2016123406A1 (en)	2015-01-28	2016-08-04	Chrono Therapeutics Inc.	Drug delivery methods and systems
WO2017004537A1 (en)	2015-07-02	2017-01-05	Centrexion Therapeutics Corporation	(4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
WO2018129304A1 (en)	2017-01-06	2018-07-12	Chrono Therapeutics Inc.	Transdermal drug delivery devices and methods
CA3101966A1 (en)	2018-05-29	2019-12-05	Morningside Venture Investments Limited	Drug delivery methods and systems
US12397141B2 (en)	2018-11-16	2025-08-26	Morningside Venture Investments Limited	Thermally regulated transdermal drug delivery system

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2985657A (en) *	1959-10-12	1961-05-23	Paul A J Janssen	1-(aroylalkyl)-4-heterocyclylpiperazines
JPS4966691A (is) *	1972-10-30	1974-06-27
US4017622A (en)	1972-12-18	1977-04-12	Dainippon Pharmaceutical Co., Ltd.	Piperazine derivatives
AT330777B (de)	1973-09-08	1976-07-26	Thomae Gmbh Dr K	Verfahren zur herstellung von neuen isochinolinderivaten und deren salzen
DK143899C (da) *	1975-04-21	1982-04-13	Merck & Co Inc	Analogifremgangsmaade til fremstilling af piperazinylpyrazinderivater
US3994898A (en) *	1975-10-16	1976-11-30	E. R. Squibb & Sons, Inc.	1,2,4-Triazolo (4,3-b) pyridazin-3-ones
NL171985C (nl) *	1976-02-10	1983-06-16	Rhone Poulenc Ind	Werkwijze voor het bereiden van preparaten met werking tegen schistosomiasis, de aldus verkregen gevormde preparaten en werkwijze voor het bereiden van 1,2-dithioolverbindingen.
GB1542030A (en) *	1976-08-19	1979-03-14	Sterling Drug Inc	Cyclic alkylidenyl n-(pyridazinyl)aminomethylenemalomates and their preparation
DE2708187A1 (de) *	1977-02-25	1978-08-31	Thomae Gmbh Dr K	Neue pyrido-pyridazin-one
HU176972B (hu) *	1977-06-13	1981-06-28	Gyogyszerkutato Intezet	Sposob poluchenija novykh proizvodnykh piridazinil-gidrazona
US4163849A (en) *	1978-03-17	1979-08-07	Merck & Co., Inc.	Piperazinylpyrazines
US4179563A (en) *	1978-05-19	1979-12-18	Warner-Lambert Company	3-Aryloxy-substituted-aminopyridines and methods for their production
JPS5618983A (en) *	1979-07-25	1981-02-23	Eisai Co Ltd	Theophylline derivative and its preapration
US4251530A (en)	1980-02-19	1981-02-17	Merck & Co., Inc.	2-{[4-(6-Substituted-2-pyrazinyl)-1-piperazinyl]alkyl}-5-substituted-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one analgesic agents
DE3034001A1 (de) *	1980-09-10	1982-04-22	Hoechst Ag, 6000 Frankfurt	Isochinolinderivate, verfahren zu ihrer hersellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung
FI70411C (fi) *	1980-12-29	1986-09-19	Pfizer	Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
US5001125A (en) *	1984-03-26	1991-03-19	Janssen Pharmaceutica N.V.	Anti-virally active pyridazinamines
JPS60226862A (ja) *	1984-03-26	1985-11-12	ジヤンセン・フア−マシユ−チカ・ナ−ムロ−ゼ・フエンノ−トシヤツプ	抗ウイルス活性ピリダジンアミン類
ES8802151A1 (es) *	1985-07-31	1988-04-01	Janssen Pharmaceutica Nv	Un procedimiento para la preparacion de nuevos piridazinaminas.
GB8603120D0 (en) *	1986-02-07	1986-03-12	Pfizer Ltd	Anti-dysrhythmia agents
GB8609630D0 (en) *	1986-04-19	1986-05-21	Pfizer Ltd	Anti-arrhythmia agents
SE8701375D0 (sv)	1987-04-02	1987-04-02	Leo Ab	Novel pyridyl- and pyrimidyl derivatives
MY104343A (en) *	1987-11-23	1994-03-31	Janssen Pharmaceutica Nv	Novel pyridizinamine deravatives
US4876256A (en)	1988-04-29	1989-10-24	Merck & Co., Inc.	Alkylpiperazinylpyridines as hypoglycemic agents
SE8803429D0 (sv)	1988-09-28	1988-09-28	Pharmacia Ab	Novel pyridyl- and pyrimidyl derivatives
US5019574A (en) *	1988-09-30	1991-05-28	Chugai Seiyaku Kabushiki Kaisha	3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function
JPH02167265A (ja) *	1988-09-30	1990-06-27	Chugai Pharmaceut Co Ltd	新規な３，４―ジアミノキノリン及びピリジン系化合物
EP0370560B1 (en)	1988-11-24	1994-01-12	Akzo Nobel N.V.	Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines
US4994456A (en) *	1989-03-01	1991-02-19	Nisshin Flour Milling Co., Ltd.	Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
JP2843632B2 (ja) *	1989-03-01	1999-01-06	日清製粉株式会社	ピリジンカルボン酸アミド誘導体
NZ233526A (en) *	1989-05-15	1991-09-25	Janssen Pharmaceutica Nv	Pyridazine derivatives and their pharmaceutical compositions
CA2071529C (en) *	1989-12-28	2001-03-20	Donna Lee Romero	Diaromatic substituted anti-aids compounds
ES2097341T3 (es) *	1991-07-03	1997-04-01	Upjohn Co	Indoles sustituidos como farmacos para el tratamiento del sida.
JPH05345764A (ja) *	1991-11-26	1993-12-27	Asahi Chem Ind Co Ltd	新規アゼピン誘導体、その製造法およびその用途
SE9201239D0 (sv)	1992-04-21	1992-04-21	Kabi Pharmacia Ab	Agents for treating substance abuse disorders
TW279864B (is) *	1993-02-19	1996-07-01	Janssen Pharmaceutica Nv
WO1994021254A1 (en) *	1993-03-17	1994-09-29	Abbott Laboratories	Substituted alicyclic amine-containing macrocyclic immunomodulators
GB9408185D0 (en) *	1994-04-25	1994-06-15	Fujisawa Pharmaceutical Co	New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
US5607936A (en) *	1994-09-30	1997-03-04	Merck & Co., Inc.	Substituted aryl piperazines as neurokinin antagonists
EP0793662A1 (en)	1994-11-23	1997-09-10	Neurogen Corporation	Aminomethyl aryl compounds; dopamine receptor subtype selective ligands
ZA97288B (en) *	1996-01-15	1998-07-14	Janssen Pharmaceutica Nv	Angiogenesis inhibiting pyridazinamines
US5929281A (en) *	1996-04-19	1999-07-27	Tosoh Corporation	Process for producing heterocyclic aromatic amine or arylamine
SE9601708D0 (sv)	1996-05-06	1996-05-06	Pharmacia Ab	Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
GB9614236D0 (en) *	1996-07-06	1996-09-04	Zeneca Ltd	Chemical compounds
JP3216566B2 (ja) *	1996-07-15	2001-10-09	東ソー株式会社	複素環式芳香族アミン類の製造方法
JP3185222B2 (ja) *	1997-01-21	2001-07-09	ウェルファイド株式会社	チオフェン化合物およびその医薬用途
DE19724980A1 (de) *	1997-06-13	1998-12-17	Basf Ag	3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
AU8457298A (en) *	1997-08-15	1999-03-08	Pfizer Products Inc.	2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor
ES2237850T3 (es) *	1997-10-14	2005-08-01	Mitsubishi Pharma Corporation	Compuestos de piperazina y su uso medicinal.
AU744539B2 (en) *	1997-10-27	2002-02-28	Neurosearch A/S	Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
GB9726736D0 (en)	1997-12-18	1998-02-18	Zeneca Ltd	Chemical compounds

1998
- 1998-10-27 AU AU97368/98A patent/AU744539B2/en not_active Ceased
- 1998-10-27 HU HU0100426A patent/HU226859B1/hu not_active IP Right Cessation
- 1998-10-27 DE DE69842058T patent/DE69842058D1/de not_active Expired - Lifetime
- 1998-10-27 TR TR2000/01171T patent/TR200001171T2/xx unknown
- 1998-10-27 NZ NZ503520A patent/NZ503520A/xx unknown
- 1998-10-27 AT AT98951286T patent/ATE278670T1/de active
- 1998-10-27 PT PT98951286T patent/PT1027336E/pt unknown
- 1998-10-27 WO PCT/DK1998/000465 patent/WO1999021834A1/en not_active Ceased
- 1998-10-27 IL IL13510898A patent/IL135108A0/xx active IP Right Grant
- 1998-10-27 EP EP04102866A patent/EP1491532B1/en not_active Expired - Lifetime
- 1998-10-27 AT AT04102866T patent/ATE491689T1/de not_active IP Right Cessation
- 1998-10-27 PL PL340224A patent/PL203140B1/pl not_active IP Right Cessation
- 1998-10-27 DE DE69826883T patent/DE69826883T2/de not_active Expired - Lifetime
- 1998-10-27 EE EEP200000178A patent/EE04588B1/xx not_active IP Right Cessation
- 1998-10-27 CZ CZ20001507A patent/CZ299499B6/cs not_active IP Right Cessation
- 1998-10-27 ES ES98951286T patent/ES2230723T3/es not_active Expired - Lifetime
- 1998-10-27 JP JP2000517946A patent/JP4570773B2/ja not_active Expired - Fee Related
- 1998-10-27 RU RU2000110744/04A patent/RU2205179C2/ru not_active IP Right Cessation
- 1998-10-27 DK DK98951286T patent/DK1027336T3/da active
- 1998-10-27 CN CN98810601A patent/CN1131211C/zh not_active Expired - Fee Related
- 1998-10-27 KR KR1020007004495A patent/KR100607838B1/ko not_active Expired - Fee Related
- 1998-10-27 BR BRPI9813279-2A patent/BR9813279B1/pt not_active IP Right Cessation
- 1998-10-27 SK SK614-2000A patent/SK285198B6/sk not_active IP Right Cessation
- 1998-10-27 CA CA2306093A patent/CA2306093C/en not_active Expired - Fee Related
- 1998-10-27 EP EP98951286A patent/EP1027336B1/en not_active Expired - Lifetime
2000
- 2000-03-16 IL IL135108A patent/IL135108A/en not_active IP Right Cessation
- 2000-03-17 US US09/528,176 patent/US6825189B1/en not_active Expired - Fee Related
- 2000-03-28 IS IS5420A patent/IS5420A/is unknown
- 2000-04-26 NO NO20002132A patent/NO317094B1/no not_active IP Right Cessation
2003
- 2003-10-03 US US10/677,240 patent/US6897219B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1491532B1 (en)	2010-12-15
US6825189B1 (en)	2004-11-30
PL203140B1 (pl)	2009-08-31
JP4570773B2 (ja)	2010-10-27
US20040072823A1 (en)	2004-04-15
SK6142000A3 (en)	2000-09-12
PL340224A1 (en)	2001-01-15
EP1491532A1 (en)	2004-12-29
CZ20001507A3 (cs)	2000-08-16
US6897219B2 (en)	2005-05-24
NO317094B1 (no)	2004-08-09
DE69826883D1 (de)	2004-11-11
IL135108A (en)	2006-12-31
HUP0100426A3 (en)	2002-03-28
DE69826883T2 (de)	2005-02-03
CZ299499B6 (cs)	2008-08-13
DK1027336T3 (da)	2005-01-24
AU744539B2 (en)	2002-02-28
TR200001171T2 (tr)	2000-10-23
HK1031378A1 (en)	2001-06-15
HUP0100426A2 (hu)	2002-02-28
EP1027336B1 (en)	2004-10-06
EP1027336A1 (en)	2000-08-16
CN1131211C (zh)	2003-12-17
KR100607838B1 (ko)	2006-08-04
IL135108A0 (en)	2001-05-20
HU226859B1 (en)	2009-12-28
JP2001521025A (ja)	2001-11-06
KR20010031461A (ko)	2001-04-16
EE200000178A (et)	2001-04-16
NO20002132D0 (no)	2000-04-26
SK285198B6 (sk)	2006-08-03
ATE491689T1 (de)	2011-01-15
NZ503520A (en)	2002-08-28
NO20002132L (no)	2000-04-26
BR9813279A (pt)	2000-08-22
ATE278670T1 (de)	2004-10-15
DE69842058D1 (de)	2011-01-27
ES2230723T3 (es)	2005-05-01
CA2306093A1 (en)	1999-05-06
EE04588B1 (et)	2006-02-15
BR9813279B1 (pt)	2010-11-16
PT1027336E (pt)	2005-01-31
WO1999021834A1 (en)	1999-05-06
RU2205179C2 (ru)	2003-05-27
CA2306093C (en)	2011-01-04
AU9736898A (en)	1999-05-17
CN1277604A (zh)	2000-12-20

Publication	Publication Date	Title
PT1027336E (pt)	2005-01-31	Heteroarildiazacicloalcanos como ligandos colinergicos de receptores nocotinicos de acetilcolina
Zhuang et al.	1994	Synthesis And Evaluation of 4-(2'-Methoxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-iodobenzamido] ethyl] piperazine (p-MPPI): A New Iodinated 5-HT1A Ligand
HUP9801887A3 (en)	1999-07-28	Cyclic amine derivatives as ccr-3 receptor antagonists, process for producing them and pharmaceutical compositions containing them
RU2005101088A (ru)	2005-06-27	Катионозамещенные дифенилазетидиноны, способ их получения, лекарственные средства, содержащие эти соединения, и их применение
HUP9802036A3 (en)	1999-06-28	Novel substituted piperazine derivatives having tachykinin receptor antagonists activity, process for producing them an pharmaceutical compositions containing them
ATE212978T1 (de)	2002-02-15	Para-substituierte phenylpropansäure derivate als integrin-antagonisten
BR0205829A (pt)	2005-03-08	Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas
ZA984637B (en)	1998-12-21	Spiro-quinuclidine derivatives their preparation and use
DE69837346D1 (de)	2007-04-26	Anilidderivate, deren herstellung und verwendung
TR199800628T2 (xx)	1998-07-21	8-Azabisiklo$3.2.1]okt-2-en t�revleri, bunlar�n haz�rlanmas� ve kullan�m�.
IL177291A0 (en)	2006-12-10	Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
YU53100A (sh)	2003-04-30	Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
ATE527247T1 (de)	2011-10-15	Benzokondensierte 5gliedrige heterocyclische verbindungen, verfahren zu deren herstellung und deren verwendung
ATE220399T1 (de)	2002-07-15	Neue naphthamid-derivate und ihre therapeutische verwendung als d3-rezeptor agonisten
ATE355842T1 (de)	2007-03-15	Neue amide, herstellung und therapeutische verwendung als modulatoren der ccr-rezeptor- aktivität
DE3261827D1 (en)	1985-02-21	1-(3-halo-2-pyridinyl)piperazines, processes for their preparation and pharmaceutical composition containing them
FI963440A0 (fi)	1996-09-03	Uudet aminohappojohdannaiset, näiden valmistusmenetelmä ja näitä yhdisteitä sisältävät farmaseuttiset seokset
PL321545A1 (en)	1997-12-08	Substituted phenyl compounds and method of applying them as endoteline antagonists
EE200000024A (et)	2000-10-16	Meetod alküüloksüfuranooni amiinderivaatide valmistamiseks, sel meetodil saadud ühendid ja nende kasutamine
FR2777780B1 (fr)	2001-05-04	Derives d'(alpha-aminophosphino) peptides, leur procede de preparation et les compositions qui les contiennent
PT880496E (pt)	2002-10-31	Compostos bifenilos e sua utilizacao como agentes estrogenicos
IS5142A (is)	1999-07-30	Kínoxalíndíón
NO931679D0 (no)	1993-05-07	Nye heterocykliske forbindelser som antagonister for eksitatoriske aminosyrereseptorer, fremgangsmaater for deres fremstilling og deres anvendelse
TR200001976T2 (tr)	2000-11-21	İzopropil-Metil [2-(3-n-propoksifenoksi)etil] amin'in hazırlanmasına yönelik usul
ATE245155T1 (de)	2003-08-15	N-substituierte 1-(butyrolacton)-isochinoline zur behandlung von nervenstörungen